Skip to main content

Day: July 29, 2024

CBMJ Completes Audited Financials – Subsidiary Patriot.TV Positioned for Growth

VENICE, FL, July 29, 2024 (GLOBE NEWSWIRE) — Conservative Broadcast Media & Journalism (PINK:CBMJ) announced that it has completed PCAOB certified audits of its most recent two years of financials. The audits are consistent with and meet requirements for uplisting to senior exchanges. The company’s CEO Mark Schaftlein stated that “Providing audited financials and continually striving to exceed reporting requirements provides greater transparency, instills confidence, and is an important step in positioning the Company as it progresses towards a senior exchange. We are very proud of our compliance and accounting departments as they definitely delivered in meeting and exceeding all standards required to smoothly complete the third-party audit. We look forward to providing additional updates and milestones now that we have...

Continue reading

Arcutis Launches ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis

Once-daily, effective, safe, and well-tolerated ZORYVE cream now commercially available Provides rapid clearance of atopic dermatitis signs and symptoms and significant reduction in itch, and can be used anywhere on the body for any duration to maintain clear skin Atopic dermatitis is the most common type of eczema, affecting approximately 9.6 million children and 16.5 million adults in the United States Management will host an investor event with a key opinion leader on Monday, July 29 at 8:30 am EDT/5:30 am PDTWESTLAKE VILLAGE, Calif., July 29, 2024 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the commercial launch of ZORYVE® (roflumilast) cream 0.15% for the treatment of mild...

Continue reading

Glass House Brands Issues an Open Letter Urging President Biden, Former President Trump and Vice President Harris to De-Schedule Cannabis

LONG BEACH, Calif. and TORONTO, July 29, 2024 (GLOBE NEWSWIRE) — Glass House Brands Inc. (“Glass House” or the “Company“) (CBOE CA: GLAS.A.U) (CBOE CA: GLAS.WT.U) (OTCQX: GLASF) (OTCQX:GHBWF), one of the fastest-growing, vertically integrated cannabis companies in the U.S., has issued an open letter to President Biden, Former President Trump and Vice President Harris urging them to completely de-schedule cannabis and to grant clemency to those incarcerated in federal prison for nonviolent marijuana offenses. Dear President Biden, Former President Trump and Vice President Harris, Our nation has spoken, and it wants federal cannabis laws to change. But, the people don’t just want cannabis rescheduling, they want complete de-scheduling. On July 22, 2024, the Drug Enforcement Administration’s (DEA) comment period...

Continue reading

Alaska Energy Metals Announces Advisory Committee Changes

VANCOUVER, British Columbia, July 29, 2024 (GLOBE NEWSWIRE) — Alaska Energy Metals Corporation (TSX-V: AEMC, OTCQB: AKEMF) (“Alaska Energy Metals”, the “Company”, or “AEMC”) today announced the reformulation of its Advisory Committee (the “Committee”). This strategic decision aligns with Alaska Energy Metals’ ongoing focus and determination to become a significant domestic source of critical and strategic energy-related metals for North America. Alaska Energy Metals President & CEO Gregory Beischer stated: “The new Committee has great depth in capital markets, finance, U.S. government policy, law, and magmatic nickel deposit geology. The Committee is a strong resource for the Company’s management team to draw upon. Paul Matysek will be instrumental with corporate introductions and executing on strategic partnerships, Clark...

Continue reading

Venus Concept Announces Regulatory Approval for Venus Bliss MAX in Canada

TORONTO, July 29, 2024 (GLOBE NEWSWIRE) — Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has received a medical device license issued by Health Canada to market the Venus Bliss MAX system in Canada. The Venus Bliss MAX was first available in the United States in early 2022 and subsequently offered in approved jurisdictions around the world. The Venus Bliss MAX is a 3-in-1 body shaping solution featuring three of Venus Concept’s market leading technologies in one complete platform, including diode laser for Fat Reduction treatments, our proprietary (MP)2 applicator that combines Multi-Polar Radio Frequency with Pulsed Electro Magnetic Fields and advanced VariPulse™ technology for Cellulite Reduction and Skin treatments, and the Company’s...

Continue reading

Amesite Announces Dramatic Increase in NurseMagic™ Users, Representing All 50 States and 6 Nations, Using App for Wide Variety of Applications

NurseMagic™ Usage Ramping Quickly, with Nursing Professionals Accessing the App Multiple Times Per Week on Tasks Ranging from Documentation to Patient Care DETROIT, July 29, 2024 (GLOBE NEWSWIRE) — Amesite Inc. (NASDAQ: AMST), a leading artificial intelligence software company offering a cloud-based learning platform for business and education markets, announced substantial growth in the user base of its app, NurseMagicTM, across all fifty (50) U.S. states and six (6) nations, within only eight (8) weeks of its public launch on June 5, following a period of availability as a gated beta product. NurseMagicTM is now delivering all key types of documentation, training and learning and support for patient communication, including translation services. Users now represent at least 27 different nursing and healthcare-related professions,...

Continue reading

Expanded Access Program Opens in the U.S. for TLX101-CDx, Telix’s Investigational Glioma (Brain Cancer) Imaging Agent

MELBOURNE, Australia, July 29, 2024 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces the opening of an expanded access program (EAP) in the United States (U.S.) for TLX101-CDx (Pixclara™1, 18F-floretyrosine or 18F-FET) an investigational positron emission tomography (PET) agent for imaging progressive or recurrent glioma, following U.S. Food and Drug Administration (FDA) agreement to proceed.         Amino acid PET is included in U.S. and European clinical practice guidelines for the imaging of gliomas2, however there is no FDA-approved targeted amino acid PET agent for brain cancer imaging currently available in the U.S. Telix’s goal is to make this product commercially available in the U.S., significantly increasing patient access to this important imaging agent for both adult...

Continue reading

Enstar Group Limited Reports Second Quarter 2024 Results

Enstar to be Acquired by Sixth Street-led Consortium for $5.1 Billion Net Income Attributable to Enstar Ordinary Shareholders of $126 Million; Return on Equity of 2.5% Primarily Driven by Positive Investment Results Year-to-Date Growth in Book Value per Ordinary Share of 4.5% to $358.74 (Fully Diluted* $350.74) Announced $400 Million Loss Portfolio Transfer with SiriusPoint Signed $350 Million Agreement to Provide Reinsurance Cover in Insurance-linked Securities (ILS) Market1 Entered into $200 Million Adverse Development Cover Agreement with Insurance Australia Group Closed $297 Million Transaction To Reinsure Legacy Business with Accredited1This transaction closed on July 25.* Non-GAAP measure; refer to “Non-GAAP Financial Measures” further below for explanatory notes and a reconciliation to the most directly comparable...

Continue reading

Enstar to be Acquired by Sixth Street for $5.1 Billion

Enstar shareholders to receive $338.00 per share in cash Strong alignment between Enstar and Sixth Street to ensure continuity of Enstar strategy HAMILTON, Bermuda, July 29, 2024 (GLOBE NEWSWIRE) — Enstar Group Limited (“Enstar”) (Nasdaq: ESGR) today announced that it has entered into a definitive merger agreement under which Sixth Street will acquire Enstar, with Liberty Strategic Capital, J.C. Flowers & Co. LLC, and other institutional investors participating in the transaction. Enstar shareholders will receive a total of $338.00 in cash per ordinary share of Enstar payable upon closing of the transaction, representing a total equity value of $5.1 billion. The consideration represents a premium of approximately 8.5% to the 90-day volume weighted average price (“VWAP”) of the company shares as of July 26, 2024, the last...

Continue reading

Rectitude Holdings Ltd Announces Fiscal Year ended March 31, 2024 Full Year Financial Results

SINGAPORE, July 29, 2024 (GLOBE NEWSWIRE) — Rectitude Holdings Ltd (the “Company” or “Rectitude”), a Singapore-based provider of safety equipment and related industrial-grade hardware products, today announced its financial results for the full year ended March 31, 2024. Fiscal Year ended March 31, 2024 Full Year Highlights (amounts in US$ unless otherwise noted):Revenues for the fiscal year ended March 31, 2024, in Singapore Dollars, increased 9.86%. Gross profit margin improved to 35.57% of revenues, up 332 basis points. Selling and marketing expenses in Singapore Dollars, increased S$1.32 million. Research and development expenses in Singapore Dollars decreased S$0.01 million. General and administrative expenses in Singapore Dollars, increased S$1.88 million. Net income was $2.49 million, or $0.20 per diluted share, for the...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.